David A. Siegel Ascendis Pharma A/S Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Two Sigma Advisers, LP holds 5,400 shares of ASND stock, worth $778,032. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,400
Previous 47,258
88.57%
Holding current value
$778,032
Previous $7.06 Million
89.47%
% of portfolio
0.0%
Previous 0.02%
Shares
4 transactions
Others Institutions Holding ASND
# of Institutions
236Shares Held
60.2MCall Options Held
80.3KPut Options Held
216K-
Ra Capital Management, L.P. Boston, MA10.1MShares$1.46 Billion22.55% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.53MShares$797 Million3.52% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.1MShares$735 Million10.24% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.45MShares$641 Million0.98% of portfolio
-
Janus Henderson Group PLC London, X04.38MShares$631 Million0.32% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $8.04B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...